EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Li Wang iD, Keshu Zhou iD, Fei Li, Qingyuan Zhang, Hui Zhou, Ou Bai, Liping Su, Chunhong Hu, Zhi-Ming Li iD, Kaiyang Ding, Qunyi Guo, Xiaoling Li und 16 weitere

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70504 ↗

Kurz gefasst

Leserbrief in der Zeitschrift HemaSphere, online erschienen am 15.10.2026. Verfasst von Li Wang und 27 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Ho…. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
  • The Affiliated Cancer Hospital of Zhengzhou University & HeNan Cancer Hospital Zhengzhou China.
  • The First Affiliated Hospital of Nanchang University Nanchang China.
  • Harbin Medical University Cancer Hospital Harbin China.
  • Hunan Cancer Hospital Changsha China.
  • The First Hospital of Jilin University Changchun China.

ORCID-Profile: Li Wang, Keshu Zhou, Zhi-Ming Li, Xiaoxi Zhou, Shuhua Yi, Wei-Li Zhao

Zitieren

APA

Wang, L., Zhou, K., Li, F., Zhang, Q., Zhou, H., Bai, O., Su, L., Hu, C., Li, Z. M., Ding, K., Guo, Q., Li, X., Zhou, X., Yu, W., Yi, S., Wei, Z., Qian, W., Chen, F., Cui, G., …, & Zhao, W. L. (2026). Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70504

Vancouver

Wang L, Zhou K, Li F, Zhang Q, Zhou H, Bai O, et al. Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study. HemaSphere. 2026;10(10). doi:10.1002/hem3.70504

BibTeX
@article{Wang2026,
  author = {Wang, Li and Zhou, Keshu and Li, Fei and Zhang, Qingyuan and Zhou, Hui and Bai, Ou and Su, Liping and Hu, Chunhong and Li, Zhi-Ming and Ding, Kaiyang and Guo, Qunyi and Li, Xiaoling and Zhou, Xiaoxi and Yu, Wenjuan and Yi, Shuhua and Wei, Zhixia and Qian, Wenbin and Chen, Feiheng and Cui, Guohui and Liang, Zhiyu and Zeng, Qingchao and Lyu, Jiaoyan and Liu, Yang and Zhang, Pan and Shen, Zhirong and Shi, Zaixing and Rong, Jing and Zhao, Wei-Li},
  title = {Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70504}
}
Kostenlos starten →